Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice

Arthritis and Rheumatism

Volumn 52, Issue 5, 2005, Pages 1522-1533

  Inoue, Atsushi ^a   Hasegawa, Hitoshi ^a   Kohno, Masashi ^a   Ito, Mitsuko R ^a   Terada, Miho ^a   Imai, Toshio ^b   Yoshie, Osamu ^c   Nose, Masato ^a   Fujita, Shigeru ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kan Research Institute ^*  (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CX3C CHEMOKINE; CX3CR1 RECEPTOR; CX3CR1 RECEPTOR BLOCKING AGENT; DNA ANTIBODY; FRACTALKINE; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 2; MESSENGER RNA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CALCIUM TRANSPORT; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GLOMERULOSCLEROSIS; GLOMERULUS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHADENOPATHY; MACROPHAGE; MESANGIUM CELL; MICROVASCULATURE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIALOADENITIS; SPLENOMEGALY; VASCULITIS;

ANIMALS; CHEMOKINES, CX3C; DISEASE PROGRESSION; KIDNEY; LUPUS NEPHRITIS; MEMBRANE PROTEINS; MICE; MICE, INBRED MRL LPR; TIME FACTORS;

EID: 18644366549     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21007     Document Type: Article

References (50)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-24.
2. Murphy ED, Roths JB. Autoimmunity and lymphoproliferation: induction by mutant gene lpr, and acceleration by a male-associated factor in strain BXSB mice. In: Rose NR, Bigazzi PE, Werner NL, editors. Genetic control of autoimmune disease. New York: Elsevier North Holland; 1979. p. 207-20.
3. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, et al. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198-215.
4. Anders HJ, Vielhauer V, Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 2003;63:401-15.
5. Kelley VR, Rovin BH. Chemokines: therapeutic targets for autoimmune and inflammatory renal disease. Springer Semin Immunopathol 2003;24:411-21.
6. Rovin BH, Rumancik M, Tan L, Dickerson J. Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest 1994;71:536-42.
7. Noris M, Bernasconi S, Casiraghi F, Sozzani S, Gotti E, Remuzzi G, et al. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995;73:804-9.
8. Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996;49:761-7.
9. Zoja C, Liu XH, Donadelli R, Abbate M, Testa D, Corna D, et al. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 1997;8:720-9.
10. Kuroiwa T, Lee EG. Cellular interactions in the pathogenesis of lupus nephritis: the role of T cells and macrophages in the amplification of the inflammatory process in the kidney. Lupus 1998;7:597-603.
11. Moore KJ, Wada T, Barbee SD, Kelley VR. Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas (lpr) mice. Kidney Int 1998;53:1631-41.
12. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein-1-dependant leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas (lpr) mice. J Exp Med 1999;190:1813-24.
13. De Lema GP, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001;12:1369-82.
14. Eriksson C, Eneslatt K, Ivanoff J, Rantapaa-Dahlqvist S, Sundqvist KG. Abnormal expression of chemokine receptors on T cells from patients with systemic lupus erythematosus. Lupus 2003;23:564-8.
15. Balabanian K, Couderc J, Bouchet-Delbos L, Amara A, Berrebi D, Foussat A, et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol 2003;170:3392-400.
16. Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003;48:2555-66.
17. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385:640-4.
18. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997;387:611-7.
19. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521-30.
20. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998;188:1413-9.
21. Chen S, Bacon KB, Li L, Garcia GE, Xia Y, Lo D, et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998;188:193-8.
22. Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, et al. Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1. Kidney Int 1999;56:612-20.
23. Ito Y, Kawachi H, Morioka Y, Nakatsue T, Koike H, Ikezumi Y, et al. Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis. Kidney Int 2002;61:2044-57.
24. Furuichi K, Wada T, Iwata Y, Sakai N, Yoshimoto K, Shimizu M, et al. Upregulation of fractalkine in human crescentic glomerulonephritis. Nephron 2001;87:314-20.
25. Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T, Alpers CE. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int 2002;62:488-95.
26. Cockwell P, Chakravorty SJ, Girdlestone J, Savage CO. Fractalkine expression in human renal inflammation. J Pathol 2002;196:85-90.
27. Ito MR, Terasaki S, Itoh J, Katoh H, Yonehara S, Nose M. Rheumatic diseases in an MRL strain of mice with a deficit in the functional Fas ligand. Arthritis Rheum 1997;40:1054-63.
28. Rossi DL, Hardiman G, Copeland NG, Gilbert DJ, Jenkins N, Zlotnik A, et al. Cloning and characterization of a new type of mouse chemokine. Genomics 1998;47:163-70.
29. Hasegawa H, Nomura T, Kohno M, Tateishi N, Suzuki Y, Maeda N, et al. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood 2000;95:30-8.
30. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991;108:193-9.
31. May LT, Sehgal PB. On the relationship between human interferon α1 and β1 genes. J Interferon Res 1985;5:521-6.
32. Hasegawa H, Utsunomiya Y, Kishimoto K, Yanagisawa K, Fujita S. SFA-1, a novel cellular gene induced by human T-cell leukemia virus type 1, is a member of the transmembrane 4 superfamily. J Virol 1996;70:3258-63.
33. Carvalho-Pinto CE, Garcia MI, Mellado M, Rodriguez-Frade JM, Martin-Caballero J, Flores J, et al. Autocrine production of IFN-γ by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. J Immunol 2002;169:1058-67.
34. Sasaki M, Hasegawa H, Kohno M, Inoue A, Ito MR, Fujita S. Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice. J Immunol 2003;170:588-96.
35. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines [review]. Annu Rev Pharmacol Toxicol 2002;42:469-99.
36. Mizoue LS, Bazan F, Johnson EC, Handel TM. Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1. Biochemistry 1999;38:1402-14.
37. Hoover DM, Mizoue LS, Handel TM, Lubkowski J. The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement. J Biol Chem 2000;275:23187-93.
38. Schaniel C, Sallusto F, Ruedl C, Sideras P, Melchers F, Rolink AG. Three chemokines with potential functions in T lymphocyte-independent and -dependent B lymphocyte stimulation. Eur J Immunol 1999;29:2934-47.
39. Greaves DR, Hakkinen T, Lucas AD, Liddiard K, Jones E, Quinn CM, et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001;21:923-9.
40. Wong BW, Wong D, McManus BM. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002;11:332-8.
41. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1 -/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003;111:333-40.
42. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003;107:1009-16.
43. Balabanian K, Foussat A, Dorfmuller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, et al. CX3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:1419-25.
44. Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, Bautch V, et al. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 2000;165:6067-72.
45. Haskell C, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, et al. Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 2001;108:679-88.
46. Ruth JH, Volin MV, Haines GK III, Woodruff DC, Katschke KJ Jr, Woods JM, et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001;44:1568-81.
47. Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Taniguchi K, et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002;46:2878-83.
48. Shiozawa F, Kasama T, Yajima N, Odai T, Isozaki T, Matsunawa M, et al. Enhanced expression of interferon-inducible protein 10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL/lpr mice. Arthritis Res Ther 2004;6:78-86.
49. Cook DN, Chen SC, Sullivan LM, Manfra DJ, Wiekowski MT, Presser DM, et al. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol 2001;21:3159-65.
50. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000;20:4106-14.